Replies to post #147849 on Biotech Values

[Summer2762]

I think based on history,

I am sorry. Which history? (tivantinib? NSCLC? P3 trials in general?)

the chances of ARQLs NSCLC pivotal trial being halted and unblinded early are essentially slim to none (much closer to none, than slim)

Do you believe that there is any chance it will be successful at the final?

PS
Any trial that's 90% powered at final is at least 20% powered at interim @50% assuming OBF.